Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia.

Sharma A, Özayral S, Caserto JS, Ten Cate R, Anders NM, Barnett JD, Kandala SK, Henderson E, Stewart J, Liapi E, Rudek MA, Franken NAP, Oei AL, Korangath P, Bunz F, Ivkov R.

Int J Hyperthermia. 2019;36(1):712-720. doi: 10.1080/02656736.2019.1631494.

PMID:
31345068
2.

Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.

van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J.

Theranostics. 2019 May 27;9(13):3674-3686. doi: 10.7150/thno.32943. eCollection 2019.

3.

Human skin long noncoding RNA WAKMAR1 regulates wound healing by enhancing keratinocyte migration.

Li D, Kular L, Vij M, Herter EK, Li X, Wang A, Chu T, Toma MA, Zhang L, Liapi E, Mota A, Blomqvist L, Gallais Sérézal I, Rollman O, Wikstrom JD, Bienko M, Berglund D, Ståhle M, Sommar P, Jagodic M, Landén NX.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9443-9452. doi: 10.1073/pnas.1814097116. Epub 2019 Apr 24.

4.

tRNAs and tRNA fragments as modulators of cardiac and skeletal muscle function.

Liapi E, van Bilsen M, Verjans R, Schroen B.

Biochim Biophys Acta Mol Cell Res. 2019 Mar 31. pii: S0167-4889(18)30509-3. doi: 10.1016/j.bbamcr.2019.03.012. [Epub ahead of print] Review.

5.

Temperature-controlled power modulation compensates for heterogeneous nanoparticle distributions: a computational optimization analysis for magnetic hyperthermia.

Kandala SK, Liapi E, Whitcomb LL, Attaluri A, Ivkov R.

Int J Hyperthermia. 2019;36(1):115-129. doi: 10.1080/02656736.2018.1538538. Epub 2018 Dec 12.

6.

Successful liver-directed gene delivery by ERCP-guided hydrodynamic injection (with videos).

Kumbhari V, Li L, Piontek K, Ishida M, Fu R, Khalil B, Garrett CM, Liapi E, Kalloo AN, Selaru FM.

Gastrointest Endosc. 2018 Oct;88(4):755-763.e5. doi: 10.1016/j.gie.2018.06.022. Epub 2018 Jul 3.

PMID:
30220303
7.

Low-Dose CT Perfusion of the Liver using Reconstruction of Difference.

Seyyedi S, Liapi E, Lasser T, Ivkov R, Hatwar R, Stayman JW.

IEEE Trans Radiat Plasma Med Sci. 2018 May;2(3):205-214. doi: 10.1109/TRPMS.2018.2812360. Epub 2018 Mar 5.

8.

Demonstration of Safety and Feasibility of Hydrogel Marking of the Pancreas-Duodenum Interface for Image Guided Radiation Therapy (IGRT) in a Porcine Model: Implications in IGRT for Pancreatic Cancer Patients.

Rao AD, Shin EJ, Beck SE, Garrett C, Kim SH, Lee NJ, Liapi E, Wong J, Herman J, Narang A, Ding K.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):640-645. doi: 10.1016/j.ijrobp.2018.02.024. Epub 2018 Mar 2.

9.

Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study.

Attaluri A, Seshadri M, Mirpour S, Wabler M, Marinho T, Furqan M, Zhou H, De Paoli S, Gruettner C, Gilson W, DeWeese T, Garcia M, Ivkov R, Liapi E.

Int J Hyperthermia. 2016 Aug;32(5):543-57. doi: 10.3109/02656736.2016.1159737. Epub 2016 May 5.

10.

Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model.

Gholamrezanezhad A, Mirpour S, Geschwind JF, Rao P, Loffroy R, Pellerin O, Liapi EA.

Eur Radiol. 2016 Oct;26(10):3474-82. doi: 10.1007/s00330-015-4197-y. Epub 2016 Jan 15.

11.

Is CT perfusion ready for liver cancer treatment evaluation?

Liapi E, Mahesh M, Sahani DV.

J Am Coll Radiol. 2015 Jan;12(1):111-3. doi: 10.1016/j.jacr.2014.10.007. No abstract available.

PMID:
25557575
12.

Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1.

Villegas VE, Rahman MF, Fernandez-Barrena MG, Diao Y, Liapi E, Sonkoly E, Ståhle M, Pivarcsi A, Annaratone L, Sapino A, Ramírez Clavijo S, Bürglin TR, Shimokawa T, Ramachandran S, Kapranov P, Fernandez-Zapico ME, Zaphiropoulos PG.

Mol Oncol. 2014 Jul;8(5):912-26. doi: 10.1016/j.molonc.2014.03.009. Epub 2014 Mar 22.

13.
14.

Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.

Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM.

Ann Surg Oncol. 2013 Nov;20(12):3779-86. doi: 10.1245/s10434-013-3127-y. Epub 2013 Jul 12.

PMID:
23846786
15.

Image quality improvements in C-Arm CT (CACT) for liver oncology applications: preliminary study in rabbits.

Tacher V, Bhagat N, Rao PV, Lin M, Schäfer D, Noordhoek N, Eshuis P, Radaelli A, Liapi E, Grass M, Geschwind JF.

Minim Invasive Ther Allied Technol. 2013 Sep;22(5):297-303. doi: 10.3109/13645706.2013.788028. Epub 2013 Jul 9.

16.

Novel local therapies in hepatocellular carcinoma.

Liapi E, Geschwind JH.

Clin Liver Dis (Hoboken). 2013 Jan 23;1(6):209-211. doi: 10.1002/cld.131. eCollection 2012 Dec. Review. No abstract available.

17.

Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?

Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF.

Radiology. 2013 Feb;266(2):636-48. doi: 10.1148/radiol.12112316. Epub 2012 Nov 9.

18.

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C.

Radiology. 2012 Oct;265(1):115-23. Epub 2012 Aug 13.

19.

Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor.

Buijs M, Vossen JA, Geschwind JF, Salibi N, Pan L, Ventura VP, Liapi E, Lee KH, Kamel IR.

J Vasc Interv Radiol. 2011 Aug;22(8):1175-80. doi: 10.1016/j.jvir.2011.03.016. Epub 2011 May 28.

20.

Transcatheter intraarterial therapies: rationale and overview.

Lewandowski RJ, Geschwind JF, Liapi E, Salem R.

Radiology. 2011 Jun;259(3):641-57. doi: 10.1148/radiol.11081489. Review.

21.

Medium-sized HCC: achieving effective local tumor control with combined chemoebolization and radiofrequency ablation.

Liapi E, Geschwind JF.

Ann Surg Oncol. 2011 Jun;18(6):1527-8. doi: 10.1245/s10434-011-1679-2. No abstract available.

22.

Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.

Liapi E, Geschwind JF, Vali M, Khwaja AA, Prieto-Ventura V, Buijs M, Vossen JA, Ganapathy-Kanniappan S, Wahl RL.

J Nucl Med. 2011 Feb;52(2):225-30. doi: 10.2967/jnumed.110.083162. Epub 2011 Jan 13. Erratum in: J Nucl Med. 2011 Mar;52(3):495. J Nucl Med. 2014 Mar;55(3):521. J Nucl Med. 2015 May;56(5):797. Ganapathy, Shanmugasudaram [Corrected to Ganapathy-Kanniappan, Shanmugasudaram].

23.

Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list.

Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, Liapi E, Georgiades CS.

Cardiovasc Intervent Radiol. 2011 Dec;34(6):1254-61. doi: 10.1007/s00270-010-0077-7. Epub 2010 Dec 30.

24.

Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?

Liapi E, Geschwind JF.

Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49. doi: 10.1007/s00270-010-0012-y. Epub 2010 Nov 12. Review.

25.

Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications.

Loffroy R, Rao P, Kwak BK, Ota S, De Lin M, Liapi E, Geschwind JF.

Korean J Radiol. 2010 May-Jun;11(3):257-68. doi: 10.3348/kjr.2010.11.3.257. Epub 2010 Apr 29. Review.

26.

Intra-arterial therapies for hepatocellular carcinoma: where do we stand?

Liapi E, Geschwind JF.

Ann Surg Oncol. 2010 May;17(5):1234-46. doi: 10.1245/s10434-010-0977-4. Epub 2010 Apr 20. Review.

PMID:
20405328
27.

Chemoembolization for primary and metastatic liver cancer.

Liapi E, Geschwind JF.

Cancer J. 2010 Mar-Apr;16(2):156-62. doi: 10.1097/PPO.0b013e3181d7e905. Review.

PMID:
20404613
28.

Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer.

Lee KH, Liapi EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF.

Cardiovasc Intervent Radiol. 2010 Jun;33(3):576-82. doi: 10.1007/s00270-010-9794-1. Epub 2010 Jan 20.

29.

Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer.

Liapi E, Geschwind JF.

J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-6. doi: 10.1007/s00534-009-0236-x. Epub 2009 Nov 5. Review.

30.

Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model.

Vossen JA, Buijs M, Geschwind JF, Liapi E, Prieto Ventura V, Lee KH, Bluemke DA, Kamel IR.

J Comput Assist Tomogr. 2009 Jul-Aug;33(4):626-30. doi: 10.1097/RCT.0b013e3181953df3.

31.

Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF.

Radiology. 2009 Feb;250(2):466-73. doi: 10.1148/radiol.2502072222.

PMID:
19188315
32.

Percutaneous US-guided implantation of Vx-2 carcinoma into rabbit liver: a comparison with open surgical method.

Lee KH, Liapi E, Buijs M, Vossen JA, Prieto-Ventura V, Syed LH, Geschwind JF.

J Surg Res. 2009 Jul;155(1):94-9. doi: 10.1016/j.jss.2008.08.036. Epub 2008 Sep 29.

33.

Considerations for implantation site of VX2 carcinoma into rabbit liver.

Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiades C, Geschwind JF.

J Vasc Interv Radiol. 2009 Jan;20(1):113-7. doi: 10.1016/j.jvir.2008.09.033. Epub 2008 Nov 22.

34.

Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions.

Vossen JA, Buijs M, Liapi E, Eng J, Bluemke DA, Kamel IR.

J Comput Assist Tomogr. 2008 Sep-Oct;32(5):750-6. doi: 10.1097/RCT.0b013e31816a6823.

35.

Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.

Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF.

Radiology. 2008 Oct;249(1):346-54. doi: 10.1148/radiol.2483071902.

PMID:
18796686
36.

Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy.

Lee KH, Liapi E, Vossen JA, Buijs M, Ventura VP, Georgiades C, Hong K, Kamel I, Torbenson MS, Geschwind JF.

J Vasc Interv Radiol. 2008 Oct;19(10):1490-6. doi: 10.1016/j.jvir.2008.06.008. Epub 2008 Aug 27.

37.

Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.

Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Ganapathy-Kanniappan S, Syed L, Wahl RL, Geschwind JF.

J Pharmacol Exp Ther. 2008 Oct;327(1):32-7. doi: 10.1124/jpet.108.141093. Epub 2008 Jun 30. Erratum in: J Pharmacol Exp Ther. 2015 Jun;353(3):560. Shanmugasundaram, Ganapathy [Corrected to Ganapathy-Kanniappan, Shanmugasundaram].

38.

Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver.

Lee KH, Liapi E, Ventura VP, Buijs M, Vossen JA, Vali M, Geschwind JF.

J Vasc Interv Radiol. 2008 Jul;19(7):1065-9. doi: 10.1016/j.jvir.2008.02.023. Epub 2008 Apr 10.

39.

Drug-eluting particles for interventional pharmacology.

Liapi E, Lee KH, Georgiades CC, Hong K, Geschwind JF.

Tech Vasc Interv Radiol. 2007 Dec;10(4):261-9. doi: 10.1053/j.tvir.2008.03.003. Review.

PMID:
18572139
40.

Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization.

Vossen JA, Kamel IR, Buijs M, Liapi E, Georgiades CS, Hong K, Geschwind JF.

J Comput Assist Tomogr. 2008 May-Jun;32(3):347-52. doi: 10.1097/RCT.0b013e318134ecd6.

PMID:
18520535
41.

Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.

Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR.

AJR Am J Roentgenol. 2008 Jan;190(1):67-73.

PMID:
18094295
42.

Transcatheter arterial chemoembolization: current technique and future promise.

Liapi E, Georgiades CC, Hong K, Geschwind JF.

Tech Vasc Interv Radiol. 2007 Mar;10(1):2-11. Review.

PMID:
17980314
43.

Platelets take up the monoclonal antibody bevacizumab.

Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5341-7. Epub 2007 Sep 12.

44.

Transcatheter and ablative therapeutic approaches for solid malignancies.

Liapi E, Geschwind JF.

J Clin Oncol. 2007 Mar 10;25(8):978-86. Review.

PMID:
17350947
45.

Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.

Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF.

J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):95-101.

PMID:
17296709
46.

Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.

Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF.

J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56.

PMID:
17296704
47.

Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.

Georgiades CS, Liapi E, Frangakis C, Park JU, Kim HW, Hong K, Geschwind JF.

J Vasc Interv Radiol. 2006 Oct;17(10):1619-24.

PMID:
17057003
48.

Incidental nonneoplastic hypervascular lesions in the noncirrhotic liver: diagnosis with 16-MDCT and 3D CT angiography.

Kamel IR, Liapi E, Fishman EK.

AJR Am J Roentgenol. 2006 Sep;187(3):682-7. Review.

PMID:
16928930
49.

Focal nodular hyperplasia: lesion evaluation using 16-MDCT and 3D CT angiography.

Kamel IR, Liapi E, Fishman EK.

AJR Am J Roentgenol. 2006 Jun;186(6):1587-96.

PMID:
16714647
50.

New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer.

Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF.

Clin Cancer Res. 2006 Apr 15;12(8):2563-7.

Supplemental Content

Support Center